Mylan and Momenta Pharmaceuticals to develop, manufacture, and commercialize six of Momenta’s current biosimilar candidates.
Mylan said today it will partner with Momenta Pharmaceuticals to develop, manufacture, and commercialize six of Momenta’s current biosimilar candidates, including Orencia® (abatacept), in a collaboration that could generate up to $245 million for Momenta, as reported by GEN magazine.
The collaboration is designed to combine Momenta’s biosimilars with Mylan's global R&D, supply chain, and commercial infrastructure. Mylan said the companies will be jointly responsible for product development, with Mylan leading worldwide commercialization efforts.
In a separate statement, Momenta said it will have an option to co-commercialize in a supporting commercial role any approved products in the U.S.
In return, Mylan agreed to pay Momenta $45 million in up-front cash, plus up to $200 million in payments tied to achieving milestones. The companies will share equally in the costs and profits of the biosimilars with respect to the products.
Momenta’s biosimilar pipeline, according to the company’s website, includes nine programs, only two of them disclosed—Orencia (M834) and the company’s lead biosimilar candidate M923, a biosimilar version of Humira® (adalimumab).
Last month, Momenta said M923 met its primary endpoint in a pharmacokinetic study comparing the biosimilar to U.S. and EU Humira reference products in patients with chronic plaque psoriasis. Momenta said it is planning its first regulatory submission for M923 in 2017, and its first commercial launch the following year.
Orencia and the seven unnamed biosimilars are in preclinical phases, with Orencia expected to advance into the clinic this year for moderate to severe rheumatoid arthritis in adults and juvenile rheumatoid arthritis.
Mylan said the partnership with Momenta will complement a biosimilars and insulin analog alliance with Biocon launched in 2009, and will position Mylan as “a definitive world leader” in biosimilars with a portfolio to 15 biosimilar or insulin analog generic products in development.
“This collaboration builds upon Mylan's existing successful biologics and insulins collaboration with Biocon, which is focused on more near-term biosimilar opportunities,” Mylan CEO Heather Bresch said in a statement.
The Biocon partnership includes programs to develop biosimilars for six compounds—trastuzumab, pegfilgrastim, adalimumab, bevacizumab, etanercept, and filgrastim—as well as three insulin analogs—glargine, lispro, and aspart. Mylan said five of those biosimilar programs have successfully completed Phase I clinical trials, while four are in Phase III studies.
Mylan and Biocon expect to submit three biosimilar applications and one insulin application in the U.S. and Europe this year. Mylan already has successfully launched its trastuzumab biosimilar product in India and other emerging markets.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.